Study identifier:D3250C00040
ClinicalTrials.gov identifier:NCT02821416
EudraCT identifier:N/A
CTIS identifier:N/A
A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
asthma
Phase 3
No
-
All
46
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2020 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Benralizumab Benralizumab administered subcutaneously | Biological/Vaccine: Benralizumab Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive |
Placebo Comparator: Placebo Placebo administered subcutaneously | Other: Placebo Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive |